Abstract： Objective： To explore the mechanism of Compound Banmao Capsules （CMC） in treating gastric cancer （GC） based on network pharmacology，bioinformatics analysis and molecular docking. Methods：The HERB database was used to screen out and correct the 11 active ingredients of CMC in combination with PubChem and SwissADME databases. Using SwissTargetPrediction database， the drug targets were obtained. The gene expression profile and clinical data of GC were obtained from the TCGA database. The differential target genes in GC were screened by R language 4.4.1 limma package，the drug targets and GC targets were intersected，and the core active ingredientintersection target network was established in Cytoscape 3.10.8 to screen the core active ingredients. Protein-protein interaction （PPI） calculation and cytoHubba functional analysis were used to further determine the core target genes. The enrichment analysis of Gene Ontology （GO） function and Kyoto Encyclopedia of Genes and Genomes （KEGG） pathway were performed on the intersection target genes based on the Metascape database. The core targets were verified in the GEO database and given the survival analysis. AutoDock 4.2.6 was used for molecular docking， and Discovery studio 4.5 was used to display some of the docking results. Results：A total of 539 active ingredients and 1 259 nonrepetitive drug targets of CMC were screened out； there were 3 141 differential target genes of GC. There were 138 intersection targets between CMC and GC. A total of 14 core target genes were obtained by PPI and cytoHubba analysis. The enrichment analysis of GO function and KEGG pathway showed that these genes were involved in the hormone metabolism，synaptic transmission and neuroactive ligand-receptor interaction，phosphatidylinositol-protein 3-kinase-Akt （PI3K-Akt） signaling pathway，and cancer signaling pathway. Four core targets of plasminogen activator inhibitor 1 （SERPINE1）， interleukin-8 （CXCL8）， angiotensin converting enzyme 2 （ACE2） and cytochrome P4502C9 （CYP2C9） were verified by GEO. Among them， SERPINE1 survival prognosis analysis P＜0.05 may be the key gene affecting the GC prognosis. The results of molecular docking showed that the main active ingredients （quercetin，kaempferol，isorhamnetin，and apigenin） of CMC had good binding activity with above four core targets. Conclusion：The active ingredients such as kaempferol，quercetin，and isorhamnetin in CMC can act on targets of SERPINE1，CXCL8，ACE2，and CYP2C9，and treat GC by regulating the cancer pathways，neuroactive ligands-receptors interaction，PI3K-Akt and other signaling pathways.